As a first-line drug for the treatment of CHD, thiazolidinedione has the most prominent cardiovascular effect on anti-atherosclerosis by triggering the target of peroxisome proliferators-activate receptor γ(PPAR-γ). The gene discussed is PPARG; the disease is coronary artery disorder.